Topics:

Medarex, Ciba Form Partnership

Medarex, Ciba Form Partnership

ANNANDALE, NJ--Medarex, Inc. and Ciba-Geigy, Ltd. have entered into an alliance for developing and marketing Medarex's MDX-210 Bispecific product. Medarex will be primarily responsible for development through phase II trials, and Ciba will be responsible for phase III trials, regulatory approvals, and commercial launch.

MDX-210 is designed to induce tumor cell killing by simultaneously binding to the HER-2 protein on the cancer cell surface and to a key receptor on immune system killer cells. The product is currently in clinical trials for the treatment of breast, ovarian, prostate, and other tumors.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.